You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Drug regulators of nitric oxide production as Alzheimer's disease therapeutics
SBC: Epigen Biosciences, Inc. Topic: NIADESCRIPTION (provided by applicant): Druggable regulators of nitric oxide production as new Alzheimer's disease therapeutics Summary: Nitrosative stress is a critical mediator of the onset and progression of Alzheimer's disease (AD): it precedes and is associated with neuritic dystrophy and dendritic spine loss, A /amyloid accumulation and deposition, cholinergic denervation and a memory ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: NIADESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation (ACI). ACI is highly prevalent in the U.S. and makes alarge contribution to public morbidity and mortality. Despite billions of dollars spent annually to treat ACI patients, current therapies lack e ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Therapeutic for Alzheimer' Disease
SBC: CoPlex Therapeutics, LLC Topic: NIADESCRIPTION (provided by applicant): Traditional approaches to drug development for Alzheimer's disease are becoming increasingly expensive and in many cases disappointingly unsuccessful. Based on preliminary in vitro and in vivo studies we have identifieda novel lactam derivative of the commonly prescribed 1,4 dihydropyridine calcium channel blocker nifedipine (1-acetyl-2,4- dimethylbenzo[c] ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Long-Term Broad-Spectrum Prevention of Implant-Related Infections
SBC: Biomedical Development Corporation Topic: NIADESCRIPTION (provided by applicant): Deep wound infection following total joint arthroplasty is a devastating complication for physician and patient, a leading cause of morbidity, and a significant economic burden to the healthcare system. With an aging population and increased life expectancies, the number of arthroplasties is expected to rise dramatically over the next 20 years. The growing numb ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
A novel vaccine against vaginal Chlamydia trachomatis
SBC: EPITOGENESIS INC Topic: NIAIDDESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients
SBC: REGENEREX, LLC Topic: NIAIDDESCRIPTION (provided by applicant): We have developed a protocol that reproducibly induces transplantation tolerance in individuals undergoing a living related donor kidney transplant. Three subjects have been off all immunosuppression for 10 months, 2 months, and 1 month respectively and have remained chimeric with stable renal function. Two additional chimeric subjects are in various stages of ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Rational Design of Live Attenuated Influenza A Vaccine Candidates
SBC: Codagenix Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Despite the availability of influenza vaccines, approximately 35,000 individuals die each year in the US alone from influenza, and influenza-related complications. The clinical impact of Influenza motivates the search for new, more effective vaccines that can be rapidly designed and easily produced. We have developed a rational, computer-aided approach to const ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Redesign of the Carbapenem Scaffold
SBC: THERAVANCE, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Carbapenemase-producing bacteria now threaten to undermine the efficacy of the carbapenems, long considered to be the most potent and reliable of the -lactam antibiotics. In Gram-negative microorganisms, in particular,the ability to produce class A serine carbapenemases, such as the plasmid-mediated KPC enzymes, or class B metallo-carbapenemases, such as the ND ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma
SBC: BUFFALO BIOLABS, LLC Topic: NCIDESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It accounts for 3.5% of all malignancies in children. Despite multimodality therapeutic treatment approaches, the outlook for patients with metastatic subtype, alveolar rhabdomyosarcoma (ARMS), remains unchange ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors.
SBC: Entrogen, Inc. Topic: NCIDESCRIPTION (provided by applicant): Development of a diagnostic biomarker for Ewing's Sarcoma family of tumors Ewing's family tumors (EFTs) are characterized by recurrent chromosomal translocations that produce chimeric fusions between the EWS gene and one of five ETS transcription factors. The expression of EWS/FLI1, the predominant fusion product in EFTs, is believed to deregulate do ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health